Phibro Animal Health (NASDAQ:PAHC) CEO Jack Bendheim Sells 14,687 Shares

Phibro Animal Health Corporation (NASDAQ:PAHC) CEO Jack Bendheim sold 14,687 shares of the business’s stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $41.68, for a total transaction of $612,154.16. Following the completion of the transaction, the chief executive officer owned 29,838 shares in the company, valued at $1,243,647.84. The trade was a 32.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Jack Bendheim also recently made the following trade(s):

• On Thursday, January 22nd, Jack Bendheim sold 13,158 shares of Phibro Animal Health stock. The shares were sold at an average price of $41.98, for a total transaction of $552,372.84.
• On Thursday, January 15th, Jack Bendheim sold 2,932 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.02, for a total value of $117,338.64.
• On Wednesday, January 14th, Jack Bendheim sold 3,651 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.53, for a total value of $147,975.03.
• On Tuesday, January 13th, Jack Bendheim sold 7,551 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.32, for a total value of $304,456.32.
• On Friday, January 9th, Jack Bendheim sold 213 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.16, for a total value of $8,554.08.
• On Wednesday, January 7th, Jack Bendheim sold 328 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.09, for a total transaction of $13,149.52.
• On Thursday, December 11th, Jack Bendheim sold 5,752 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.93, for a total transaction of $235,429.36.
• On Tuesday, December 9th, Jack Bendheim sold 1,288 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.19, for a total transaction of $51,764.72.
• On Monday, December 8th, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The stock was sold at an average price of $40.06, for a total transaction of $141,011.20.
• On Wednesday, December 3rd, Jack Bendheim sold 3,520 shares of Phibro Animal Health stock. The shares were sold at an average price of $40.77, for a total transaction of $143,510.40.

Phibro Animal Health Trading Down 0.8%

NASDAQ:PAHC traded down $0.34 during trading hours on Thursday, reaching $41.61. 212,999 shares of the stock were exchanged, compared to its average volume of 197,450. Phibro Animal Health Corporation has a twelve month low of $16.16 and a twelve month high of $46.42. The company has a quick ratio of 1.35, a current ratio of 3.09 and a debt-to-equity ratio of 2.32. The business has a 50-day moving average of $40.28 and a two-hundred day moving average of $37.41. The company has a market capitalization of $1.69 billion, a price-to-earnings ratio of 25.07, a PEG ratio of 1.16 and a beta of 0.79.

Phibro Animal Health (NASDAQ:PAHC) last posted its earnings results on Wednesday, November 5th. The company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.15. The firm had revenue of $363.89 million for the quarter, compared to analyst estimates of $345.44 million. Phibro Animal Health had a return on equity of 36.26% and a net margin of 4.85%.Phibro Animal Health has set its FY 2026 guidance at 2.640-2.810 EPS. On average, equities analysts predict that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, December 17th. Shareholders of record on Wednesday, November 26th were paid a $0.12 dividend. The ex-dividend date was Wednesday, November 26th. This represents a $0.48 annualized dividend and a dividend yield of 1.2%. Phibro Animal Health’s payout ratio is 28.92%.

Institutional Investors Weigh In On Phibro Animal Health

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PAHC. Capricorn Fund Managers Ltd purchased a new stake in Phibro Animal Health in the 3rd quarter valued at $10,233,000. JPMorgan Chase & Co. boosted its stake in shares of Phibro Animal Health by 1,730.9% during the third quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company’s stock worth $9,634,000 after buying an additional 225,110 shares during the period. Allspring Global Investments Holdings LLC acquired a new position in Phibro Animal Health in the 3rd quarter valued at about $8,931,000. Ranger Investment Management L.P. raised its stake in Phibro Animal Health by 101.1% during the 2nd quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company’s stock valued at $9,143,000 after acquiring an additional 179,975 shares during the last quarter. Finally, Millennium Management LLC lifted its position in Phibro Animal Health by 74.3% during the 1st quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock worth $7,733,000 after acquiring an additional 154,281 shares during the period. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on PAHC shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of Phibro Animal Health in a research note on Monday, December 29th. JPMorgan Chase & Co. raised their price objective on shares of Phibro Animal Health from $45.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, November 7th. Finally, Zacks Research upgraded shares of Phibro Animal Health from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, December 9th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $31.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.